Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

15 analysts have expressed a variety of opinions on Vertex Pharmaceuticals VRTX over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...

In the preceding three months, 19 analysts have released ratings for Vertex Pharmaceuticals VRTX, presenting a wide array of perspectives from bullish to bearish. The table below provides a ...

Jessica Fye has given her Buy rating due to a combination of factors that highlight Vertex Pharmaceuticals’ promising developments, particularly concerning their drug suzetrigine. The recent ...

David Risinger has given his Buy rating due to a combination of factors related to Vertex Pharmaceuticals’ recent positive developments. The company disclosed promising Phase 3 trial results for ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options begin trading today, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Vertex Pharmaceuticals fair value estimate is US$855 Current... BOSTON, October 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq ...